HCT 3012: Phase I started

NicOx began a double-blind, crossover, U.S. Phase I trial comparing HCT 3012 to rofecoxib. Merck & Co. Inc. (MRK, Whitehouse Station, N.J.) markets Vioxx rofecoxib. ...